Voyager Therapeutics’ (VYGR) “Buy” Rating Reiterated at HC Wainwright

HC Wainwright reissued their buy rating on shares of Voyager Therapeutics (NASDAQ:VYGR) in a research note published on Monday,Benzinga reports. HC Wainwright currently has a $30.00 price target on the stock.

A number of other research firms have also commented on VYGR. Leerink Partners began coverage on shares of Voyager Therapeutics in a research note on Wednesday, October 16th. They issued an “outperform” rating and a $15.00 price objective on the stock. Wedbush assumed coverage on Voyager Therapeutics in a research report on Friday, November 29th. They issued an “outperform” rating and a $11.00 price objective for the company. Canaccord Genuity Group reaffirmed a “buy” rating and set a $14.00 target price on shares of Voyager Therapeutics in a research note on Thursday, November 14th. Cantor Fitzgerald started coverage on Voyager Therapeutics in a research note on Friday, January 10th. They issued an “overweight” rating and a $5.73 price target on the stock. Finally, Leerink Partnrs raised shares of Voyager Therapeutics to a “strong-buy” rating in a research report on Wednesday, October 16th. One research analyst has rated the stock with a hold rating, eight have assigned a buy rating and one has given a strong buy rating to the company. According to MarketBeat, the stock has a consensus rating of “Buy” and an average price target of $15.97.

Voyager Therapeutics Stock Down 1.4 %

VYGR stock opened at $5.52 on Monday. Voyager Therapeutics has a twelve month low of $4.99 and a twelve month high of $10.66. The company has a market cap of $301.54 million, a price-to-earnings ratio of 7.77 and a beta of 0.93. The business has a 50 day moving average price of $5.82 and a two-hundred day moving average price of $6.57.

Voyager Therapeutics (NASDAQ:VYGR) last announced its quarterly earnings results on Tuesday, November 12th. The company reported ($0.16) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.45) by $0.29. The firm had revenue of $24.63 million for the quarter, compared to the consensus estimate of $12.63 million. Voyager Therapeutics had a return on equity of 8.33% and a net margin of 15.80%. During the same quarter in the previous year, the business earned ($0.59) earnings per share. On average, equities research analysts anticipate that Voyager Therapeutics will post -0.91 EPS for the current fiscal year.

Insider Transactions at Voyager Therapeutics

In other news, COO Robin Swartz sold 6,500 shares of the stock in a transaction on Monday, December 23rd. The stock was sold at an average price of $5.65, for a total transaction of $36,725.00. Following the completion of the transaction, the chief operating officer now owns 112,328 shares in the company, valued at approximately $634,653.20. This represents a 5.47 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders sold a total of 10,778 shares of company stock worth $58,548 in the last quarter. 4.53% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Voyager Therapeutics

A number of institutional investors and hedge funds have recently added to or reduced their stakes in VYGR. Hunter Perkins Capital Management LLC boosted its holdings in Voyager Therapeutics by 3.3% in the 3rd quarter. Hunter Perkins Capital Management LLC now owns 64,040 shares of the company’s stock worth $375,000 after buying an additional 2,025 shares during the period. Empowered Funds LLC boosted its holdings in shares of Voyager Therapeutics by 5.4% in the third quarter. Empowered Funds LLC now owns 44,809 shares of the company’s stock worth $262,000 after acquiring an additional 2,278 shares during the period. Charles Schwab Investment Management Inc. grew its position in shares of Voyager Therapeutics by 2.6% in the third quarter. Charles Schwab Investment Management Inc. now owns 137,477 shares of the company’s stock valued at $804,000 after purchasing an additional 3,473 shares in the last quarter. China Universal Asset Management Co. Ltd. raised its stake in shares of Voyager Therapeutics by 64.1% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 10,489 shares of the company’s stock valued at $61,000 after purchasing an additional 4,098 shares during the period. Finally, The Manufacturers Life Insurance Company lifted its holdings in Voyager Therapeutics by 6.0% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 94,398 shares of the company’s stock worth $747,000 after purchasing an additional 5,365 shares in the last quarter. Institutional investors own 48.03% of the company’s stock.

About Voyager Therapeutics

Voyager Therapeutics, Inc, a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial.